Martin Mynarek
Overview
Explore the profile of Martin Mynarek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Traunwieser T, Loos E, Ottensmeier H, Gastberger K, Nemes K, Mynarek M, et al.
Pediatr Blood Cancer
. 2024 Feb;
71(5):e30910.
PMID: 38342954
Background: The contribution of tumor type, multimodal treatment, and other patient-related factors upon long-term cognitive sequelae in infant brain tumor survivors remains undefined. We add our retrospective analysis of neuropsychological...
12.
Neyazi S, Yamazawa E, Hack K, Tanaka S, Nagae G, Kresbach C, et al.
Acta Neuropathol
. 2024 Jan;
147(1):22.
PMID: 38265489
Ependymomas encompass multiple clinically relevant tumor types based on localization and molecular profiles. Tumors of the methylation class "spinal ependymoma" (SP-EPN) represent the most common intramedullary neoplasms in children and...
13.
Obrecht-Sturm D, Pfaff E, Mynarek M, Bison B, Rodehuser M, Becker M, et al.
J Neurooncol
. 2024 Jan;
166(2):359-368.
PMID: 38253790
Purpose: To provide a treatment-focused review and develop basic treatment guidelines for patients diagnosed with pineal anlage tumor (PAT). Methods: Prospectively collected data of three patients with pineal anlage tumor...
14.
Schoof M, Godbole S, Albert T, Dottermusch M, Walter C, Ballast A, et al.
Nat Commun
. 2023 Nov;
14(1):7717.
PMID: 38001143
Pediatric high-grade gliomas of the subclass MYCN (HGG-MYCN) are highly aggressive tumors frequently carrying MYCN amplifications, TP53 mutations, or both alterations. Due to their rarity, such tumors have only recently...
15.
Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology
Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, et al.
Nat Med
. 2023 Oct;
30(1):306.
PMID: 37875569
No abstract available.
16.
Afflerbach A, Rohrandt C, Brandl B, Sonksen M, Hench J, Frank S, et al.
Clin Chem
. 2023 Aug;
70(1):250-260.
PMID: 37624932
Background: Molecular brain tumor diagnosis is usually dependent on tissue biopsies or resections. This can pose several risks associated with anesthesia or neurosurgery, especially for lesions in the brain stem...
17.
Inhestern L, Herrmann J, Schurmann J, Meister R, Nawka M, Mynarek M, et al.
Child Care Health Dev
. 2023 Aug;
50(1):e13157.
PMID: 37581953
Background: Assessing patient experiences is essential to provide high quality health-care. The objectives of this study were to examine (1) child- and parent-reported information status before magnetic resonance imaging (MRI),...
18.
Funke V, Sandmann S, Melcher V, Seggewiss J, Horvath J, Jager N, et al.
Acta Neuropathol Commun
. 2023 Jul;
11(1):124.
PMID: 37501103
To date, several studies on genomic events underlying medulloblastoma (MB) biology have expanded our understanding of this tumour entity and led to its division into four groups-WNT, SHH, group 3...
19.
Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M, et al.
Neuro Oncol
. 2023 Jun;
25(12):2273-2286.
PMID: 37379234
Background: The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here,...
20.
Ng C, Obrecht D, Wells O, Zapotocky M, Sumerauer D, Coltin H, et al.
Neurooncol Adv
. 2023 Jun;
5(1):vdad057.
PMID: 37287693
Background: (formerly known as fused supratentorial ependymoma (fus ST-EPN) has been recognized as a novel entity in the 2016 WHO classification of CNS tumors and further defined in the recent...